

Endosafe® Trillium® Recombinant Cascade Reagent Validation Approach

Alan Hoffmeister Senior Global Scientific Portfolio Specialist





Recombinant Factor C (rFC) versus Recombinant Cascade Reagent (rCR)



Natural LAL Cascade


Recombinant Factor C








Natural LAL Cascade Reagent









Endosafe[®] Trillium[®] Recombinant Cascade Reagent



Advancing Responsible Science through Sustainable Endotoxin Testing Solutions

Endosafe LAL Cartridge Technology



- + 95% Reduction in horseshoe crab blood from Gel-Clot.
- + FDA-Licensed and compliant with harmonized Pharmacopeia chapters.
- + Robust and scalable technology, from single test to full automation.

Endosafe Trillium Recombinant Cascade Reagent (rCR) Vial



- + **100% Replacement** in horseshoe crab blood.
- + Optimized kinetic chromogenic reagent formulated to simulate the natural LAL reaction.
- Compatible with existing plate readers and supported by Endoscan-V software.


Endosafe Trillium rCR Cartridge Technology



- + **100% Replacement** in horseshoe crab blood.
- Optimized kinetic chromogenic reagent formulated to simulate the natural LAL reaction.
- Seamless integration with existing suite of scalable, automated, Endosafe cartridge technology platforms & Endoscan-V software.

Sustainable Endotoxin Testing Complete Solution

A complete, sustainable, and scalable BET Portfolio





Conclusion for Interference Patterns

107 non-water samples tested

- 104 samples worked at the same dilution for both LAL / rCR
- 2 samples worked at a lower dilution for rCR (1:1 vs 1:10 & 1:1k vs 1:2k)
- 1 sample required further dilution for rCR (1:1k vs. 1:5k)*

rCR has similar interference patterns to LAL for > 99% of the samples tested.

* MVD unknown due to lack of completed information from manufacturer

https://www.criver.com/resources/download-ms-endosafe-trillium-rcr-beta-study-technical-report

Sample Category	Number Tested
Small Molecule	23
Raw materials	17
Plasmid	14
Lentivirus	11
Capsid	10
Injectables	9
Large Molecule	6
Biologicals	5
Vaccine	2
MAB	2
Adenovirus	1
Devices	1
Cell Supernatant	1
Other	3






Endosafe[®] Trillium[®] Recombinant Cascade Reagent

Vials & Cartridges Validation Approach



Endosafe® Trillium – Validation strategy & Support Services

Vials & Cartridges





Endosafe® Trillium – Risk Assessment Potential Scenarios For Validation Strategy

Vials & Cartridges

		Parameters required by ICH Q2 for an analytical method			I	
		Water		Product or intermediate (Dossier submitted)		
		WFI	PW	Approach 1	Approach 2	Approach 3
Accuracy						
Precision	Repeatability					
	Intermediate Precision					
Range						
Linearity						
Limit of detection						
Specificity						

Robustness	rCR only				
Equivalency (rCR to LAL)					


Trillium Primary Validation Package	Performed by Charles River with LAL and rCR
Product Specific Validation	Performed by the customer with rCR





Product Specificity (Method Suitability)

CR recommended Parameters to be assessed on per product basis




CR strongly recommend the user perform a risk assessment to determine approach to validation



COPYRIGHT 2024 CHARLES RIVER LABORATORIES

Product Specificity (Method Suitability)

CR recommended Parameters to be assessed on per product basis - Plate template example



Performed by the customer or Outsource Service Offered by Charles River



Product Specificity (Method Suitability)

CR recommended Parameters to be assessed on per product basis - Example



COPYRIGHT 2024 CHARLES RIVER LABORATORIES

chanes river



Regulatory

Landscape for

Recombinant BET

idan Pharmacopoeia Conninsi idan Pharmacopoeia Conninsi idan Pharmacopoeia Conninsi igan Pharmacopoeia Conninsi ig





Brazilian pharmacopeia National Form









European Directorate for the Quality of Medicines & HealthCare

Global Regulatory Agencies Not Aligned

Current Position


	Endotoxin Testing			
	LAL	rFC	rCR	
Ph. Eur.	Accepted	Accepted*	In Discussion	
WHO	Accepted	Proposed*	Alternative	
USP	Accepted	Accepted*†	Accepted*†	
Japan	Accepted	Alternative	Alternative	
India	Accepted	Proposed*	Proposed*	
China	Accepted	Alternative	Alternative	
S. Korea	Accepted	Alternative	Alternative	
Brazil	Accepted	Proposed*	Alternative	

*Alternative method validation required, when the chapter is not referenced in mandatory product specific monographs. †Chapter <86> approved 26 July 2024. Final text to be published November 2024 for early adoption and becomes official May 2025






Conclusions



Endosafe Trillium

The advantages of a recombinant cascade reagent (rCR)





18



Contact Us

1-877-CRIVER-1 askcharlesriver@crl.com www.criver.com

Alan Hoffmeister Senior Global Scientific Portfolio Specialist alan.hoffmeister@crl.com

